Ruben Rizzi | SVP Global Regulatory Affairs, Safety & Pharmacovigilance
BioNTech SE
Ruben Rizzi, MD, SVP of Global Regulatory Affairs, Safety & Pharmacovigilance at BioNTech. I joined the company in December 2019 just before the pandemic, and I have been the global regulatory lead for BioNTech for our COVID-19 development. Currently I am co-leading the Global Regulatory Affairs and leading the Medical Safety & Pharmacovigilance departments at BioNTech, working closely with the teams that are responsible for the development of BioNTech´s pipeline, post-approval activities and labelling for all infectious diseases, rare diseases and immuno-oncology candidates.
Appearances:
Pre-Congress Workshops (19th October) @ 10:00
BioNTech’s Oncology Pipeline: Combining mRNA Cancer Immunotherapies with Next-Gen Immunomodulators and Targeted Therapies
Pre-Congress Workshops (19th October) @ 15:00
Panel: Global Vaccine Access: Balancing Speed and Safety
- Where do reliance and expedited pathways genuinely speed access without compromising safety?
- What has worked, and what has broken down, in real regulatory submissions?
- How do we move from pilots and one-off successes to predictable, trusted pathways?
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events